if you are interested in cellestis., page-2

stuffed up the above....here is the rest.



3. Agenda of Feb AFEB meeting at which a presentation will be made by Jim Rothel (CST), A presentation will be made by Dr Mazurek (CDC) re the comparison of QF and TST (his report is already published and is very favourable towards QFTB) and the board will be addressing the Question raised in 2, above.

There is lots more of this stuff but the above is a pretty good straight through timeline, bringing us up to current.

In summary, there is little doubt in my mind that the AFEB recomendation will come down in favour of Quantiferon-TB from Cellestis. Originally, these matters were expected to be addressed at the September meeting but were delayed because of the terrorist issues that were addressed instead.